| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Outline of Final Research Achievements |
The purpose of this research is to reveal the EphA10 function in both breast cancer tissues and normal tissues, for development of an anti-EphA10 antibody drug in refractory breast cancer cases. The function analysis of EphA10 in breast cancer cells showed that EphA10 promoted breast cancer cell proliferation, suggesting that Clone: LBR inhibited tumor growth by CDC or neutralizing activity. On the other hand, the function analysis of EphA10 in testis tissues showed that EphA10 might inhibit the tissue growth and testosterone secretion. Furthermore, we could successfully isolate human anti-EphA10 monoclonal antibody candidates for clinical trials. Consequently, we hope that the findings contribute to the development of effective and safe antibody drugs.
|
